FDMT
4D Molecular Therapeutics Inc
13.70$
-1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 124.1% | – | 99,535.7% | 637,200.0% | 1,282,800.0% | 178,400.0% | 290,707.1% | 319,673.3% | 52,486.7% | 2.3% | 67.4% | 55.2% | 58.0% | |
| -24.1% | – | -99,435.7% | -637,100.0% | -1,282,700.0% | -178,300.0% | -290,607.1% | -319,573.3% | -52,386.7% | 97.7% | 32.6% | 44.8% | 42.0% | |
| 124.1% | – | 99,535.7% | 637,200.0% | 1,282,800.0% | 4,308,500.0% | 290,707.1% | 319,673.3% | 54,931.1% | 67.7% | 2,132.6% | 1,805.9% | 261.2% | |
| 45.1% | – | 36,764.3% | 212,020.0% | 421,700.0% | 1,303,300.0% | 92,400.0% | 76,800.0% | 13,152.2% | 15.0% | 383.6% | 331.2% | 53.1% | |
| 45.1% | – | 36,764.3% | 212,020.0% | 421,700.0% | 5,433,400.0% | 92,400.0% | 76,800.0% | 15,596.7% | 80.4% | 2,448.7% | 2,081.9% | 256.2% | |
| -69.2% | – | -136,200.0% | -849,120.0% | -1,704,400.0% | -5,611,700.0% | -383,007.1% | -396,373.3% | -67,983.3% | 17.3% | -2,416.1% | -2,037.2% | -214.2% | |
| -50.8% | – | -115,717.9% | -699,060.0% | -1,461,433.3% | -4,967,100.0% | -342,657.1% | -364,386.7% | -63,195.6% | 22.8% | -2,256.6% | -1,929.0% | -194.7% | |
| -19.2% | – | 0.0% | – | – | 0.1% | – | – | – | – | – | – | – | |
| -50.8% | – | -115,717.9% | -699,060.0% | -1,461,433.3% | -4,967,100.0% | -342,657.1% | -364,386.7% | -63,195.6% | 22.8% | -2,256.6% | -1,929.0% | -194.7% | |
| -45.8% | – | -111,528.6% | -675,180.0% | -1,404,666.7% | -4,788,700.0% | -330,128.6% | -356,613.3% | -61,794.4% | 14.6% | -2,189.2% | -1,981.9% | -200.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.